EBIDTA for the quarter stood at Rs 246.0 million
Indoco Remedies announced its un-audited results for the fourth quarter of the financial year 2011-12 by the board of directors of the company.
The company has recorded a growth of 22.4 per cent in the revenues at Rs 1476.6 million as compared to Rs 1206.3 million over the same quarter last year, during the fourth quarter of FY 2011-12. For the full year, the company registered a growth of 16.9 per cent at Rs 5601.3 million as compared to Rs 4790.6 million over last year. The EBIDTA for the quarter stood at Rs 246.0 million as compared to Rs 200.4 million over the same quarter last year and the EBIDTA for the year stood at Rs 953.9 million as compared to Rs 770.6 million last year.
Commenting on the performance, Aditi Kare Panandikar, Managing Director, said, “Indoco has done fairly well inspite of a slowdown in the economy. However, we have a highly optimistic view of the future and are all set to take a big leap both in domestic as well as international business.”
Sundeep V Bambolkar, Joint Managing Director, added, “With the required infrastructure in place, well chosen product pipeline and alliances with the top generic companies of the world, it is time for Indoco to embark on the next horizon of the success curve.”
EP News Bureau — Mumbai